Cargando…

Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer

Angiogenesis pathway genes show substantial genetic variability causing inter-individual differences in responses to anti-angiogenic drugs. We examined 20 single nucleotide polymorphisms (SNPs) in 13 of these genes to predict tumour response and clinical outcome measured as progression free survival...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaibar, María, Galán, Miguel, Romero-Lorca, Alicia, Antón, Beatriz, Malón, Diego, Moreno, Amalia, Fernández-Santander, Ana, Novillo, Apolonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866547/ https://www.ncbi.nlm.nih.gov/pubmed/33573134 http://dx.doi.org/10.3390/ijms22031381

Ejemplares similares

miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Romero-Lorca, Alicia, et al.
Publicado: (2021)

Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
por: Novillo, Apolonia, et al.
Publicado: (2020)

FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
por: Gaibar, María, et al.
Publicado: (2022)

HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
por: Novillo, Apolonia, et al.
Publicado: (2023)

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
por: Romero-Lorca, Alicia, et al.
Publicado: (2015)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

Differential expression of PMCA2 mRNA isoforms in a cohort of Spanish patients with breast tumor types
por: Romero-Lorca, Alicia, et al.
Publicado: (2018)

Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer
por: Novillo, Apolonia, et al.
Publicado: (2021)

Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients
por: Makhoul, Issam, et al.
Publicado: (2017)

Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients
por: Fernández-Santander, Ana, et al.
Publicado: (2013)

Pharmacogenetics of ugt genes in North African populations
por: Gaibar, M., et al.
Publicado: (2018)

Clonal Dominance With Retroviral Vector Insertions Near the ANGPT1 and ANGPT2 Genes in a Human Xenotransplant Mouse Model
por: Haemmerle, Reinhard, et al.
Publicado: (2014)

Tissue-specific epigenetics of atherosclerosis-related ANGPT and ANGPTL genes
por: Ehrlich, Kenneth C, et al.
Publicado: (2019)

Angpt2/Tie2 autostimulatory loop controls tumorigenesis
por: Karabid, Ninelia Minaskan, et al.
Publicado: (2022)

Genetic association of ANGPT2 with primary open-angle glaucoma
por: He, Jing Na, et al.
Publicado: (2022)

Immune-related gene ANGPT1 is an adverse biomarker for endometrial carcinoma
por: Nong, Binbin, et al.
Publicado: (2021)

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2018)

0737. Statins protect the vasculature from excessive angpt-2 production in sepsis
por: Thamm, K, et al.
Publicado: (2014)

Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma
por: Qin, Shuang, et al.
Publicado: (2020)

ANGPT1 methylation and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage patients
por: Liu, Dongjing, et al.
Publicado: (2021)

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2019)

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial
por: Aranda, Enrique, et al.
Publicado: (2020)

Immunoregulation and clinical significance of neutrophils/NETs-ANGPT2 in tumor microenvironment of gastric cancer
por: Yang, Shifeng, et al.
Publicado: (2022)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer
por: Murillo, Serafin Morales, et al.
Publicado: (2021)

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
por: Gong, Hongyu, et al.
Publicado: (2023)

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2018)

Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer
por: van Nassau, Sietske C., et al.
Publicado: (2021)

FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
por: Antoniotti, Carlotta, et al.
Publicado: (2022)

Transcriptional repression of ANGPT1 by histone H3K9 demethylase KDM3B
por: Han, Arim, et al.
Publicado: (2015)

ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT
por: Lin, Chen-Yuan, et al.
Publicado: (2017)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
por: Marisi, Giorgia, et al.
Publicado: (2019)

Biallelic ANGPT2 loss-of-function causes severe early-onset non-immune hydrops fetalis
por: Smeland, Marie F., et al.
Publicado: (2023)

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study(†)
por: Iwamoto, S., et al.
Publicado: (2015)

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2020)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Neurological Toxicity in Metastatic Colorectal Cancer Patients Treated with Modified FOLFOX6 Plus Bevacizumab
por: Otsu, Satoshi, et al.
Publicado: (2014)

Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case Report
por: Arias Ron, David, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t7qveie85fscnapb9ioq25avqb